Table 2 Pre-operative variables

Number of cases

151

57

Non-modifiable

 Average age (years)

85.50 (SD 6.87) (65;103)

85.96 (SD 6.65) (65;96)

0.359^c

 Sex (male/female) %

0.883^b

  Female

118 (78.1%)

44 (77.2%)

  Male

33 (21.9%)

13 (22.8%)

 Side

0.621^b

  Left

64 (42.4%)

22 (38.6%)

  Right

87 (57.6%)

35 (61.4%)

Modifiable

 Social situation

0.886^b

  At home alone

22 (14.6%)

7 (12.3%)

  At home accompanied

80 (53.0%)

30 (52.6%)

  Institutionalised

49 (32.5%)

20 (35.1%)

 Dependency

  Barthel’s index

74.47 (SD 22.24) (15;100)

76.41 (SD 19.63) (10;100)

0.823^c

 Comorbidity

  Charlson Comorbidity Index (not age-adjusted)

2.12 (SD 1.36) (0;7)

2.25 (SD 1.04) (0;4)

0.209^c

  Charlson Comorbidity Index (age-adjusted)

6.09 (SD 1.37) (4;11)

6.17 (SD 1.05) (4;8)

0.277^c

 Cognitive impairment (Pfeiffer’s)

0.306^b

  None

28 (18.5%)

8 (14.0%)

  Mild

97 (64.2%)

40 (70.2%)

  Moderate

26 (17.2%)

8 (14.0%)

  Severe

0 (0%)

1 (1.8%)

 Osteoporosis (previous fractures, Nuti’s definition)

0.769^b

  None

85 (56.3%)

36 (63.2%)

  Traumatic (non-osteoporotic)

5 (3.3%)

1 (1.8%)

  Osteoporotic:

   Hip

12 (7.9%)

3 (5.3%)

   Other locations

38 (28.6%)

6 (33.3%)

   Both

5 (3.0%)

3 (5.3%)

 Previous osteoporosis treatment*

0.596^b

  No

129 (85.4%)

47 (82.5%)

  Yes

22 (14.6%)

10 (17.5%)

APT/ACT

0.06^b

 None

87 (57.6%)

32 (56.1%)

 Acetylsalicylic acid 100 mg

23 (15.2%)

19 (31.6%)

 Acetylsalicylic acid 300 mg

16 (10.6%)

1 (1.8%)

 Clopidogrel

1 (0.7%)

0 (0%)

 Acenocumarol

21 (13.9%)

5 (8.8%)

 Direct Xa inhibitors

2 (1.3%)

1 (2.2%)

 LMWH

1 (0.7%)

1 (1.8%)

ASA Risk Score

3 (1;4)

2 (1;4)

0.893^d